Bharat Biotech Ltd is an Hyderabad-based Research institute which announced recently that it had bagged the World Health Organization (WHO) prequalification tag for its rotavirus vaccine, ROTAVAC for treating diarrhoeal disease.
The WHO prequalification other than Unicef, GAVI and Pan-American Health Organization paves the way for health and humanitarian organizations to procure it for public health vaccination programmes across the world.
- Rotavirus is believed to be the most common cause of diarrhoeal disease and kills more than 200,000 children every year and is targeted mostly to infants and young children , Because at least once by the age of five Nearly every child in the world gets infected with rotavirus and is also estimated to be the main cause of deaths of nearly 80 thousand children under age of 5 years and up to 10 lakh hospitalizations each year.According to the data of 2013, rotavirus is believed to have claimed life of almost 37 percent of children from diarrhoea and 215,000 deaths worldwide.
- Transmitted by the fæcal-oral route, via contact with contaminated hands, surfaces and objects Rotavirus is also transmitted possibly by the respiratory route.
- Bharat Biotech Limited is a Hyderabad-based Research institute which is the developed of ROTAVAC.
- India introduced ROTAVAC into its national immunization programme during 2016 and is estimated to provide 35 million doses till date.
- ROTAVAC will be supplied to low income countries at $1.0/dose or approx 60 INR/dose in case of india and the company aims to provide the same in other countries like Nigeria, Congo and other African nations which forms some low income nations.
- It is developed under public-private partnership (PPP) model (joint collaboration of India and United States) that involved Ministry of Science and Technology (India) and institutions of the US Government and NGOs such as supported by Bill and Melinda Gates Foundation.